OSLO, Norway, May 9, 2019 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2019 results. A meeting for investors, analysts and press will take place in Oslo …

Source: https://www.prnewswire.com:443/news-releases/targovax-asa-first-quarter-2019-results-300846984.html

This entry was posted on Thursday, May 9th, 2019 at 12:15 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.